The phase Ib two-part (dose escalation and expansion) six-cohort TROPION-Lung02 study evaluated datopotamab deruxtecan (Dato-DXd) plus pembrolizumab with or without platinum-based chemotherapy (Pt-CT) in patients with advanced or metastatic NSCLC (amNSCLC) without actionable genomic alterations.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 21 Mar 2026.
The item focuses on Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.
Review the original article for the full source wording and details.